![Page 1: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/1.jpg)
1
Office of Biostatistics Center of Drug Evaluation and Research, FDA
Presented at ASA Caucus of Academic Representatives
Ram Tiwari, Ph.D.Office of Biostatistics
Center for Drug Evaluation and ResearchU.S. Food and Drug Administration
![Page 2: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/2.jpg)
2
Outline • FDA location and Organizational Charts • What FDA statisticians do - Review of Drug Products - Presentations at Advisory Committees - Write Guidance Documents for Industry - Regulatory Research and Professional Activities - Training, Communication and Outreach• Career Opportunities at FDA
![Page 3: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/3.jpg)
3
FDA White Oak Campus, Silver Spring, MD
OB/Building 21
![Page 4: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/4.jpg)
4
10 10 70 150 40 10
290 Statisticians at FDA and Growing!
New Center
![Page 5: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/5.jpg)
5
CDER ORGANIZATIONa condensed version
CDER
PharmaceuticalSciences
New DrugsSurveillance &Epidemiology
TranslationalSciences
ClinicalPharmacology Biostatistics
![Page 6: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/6.jpg)
6
CDER Office of BiostatisticsDirector: Robert T. O’Neill
DB1 Cardiovascular & Renal; Neurological; Psychiatric
DB2 Pulmonary & Allergy; Metabolism & Endocrine; Analgesics & Anesthetics
DB3 Gastrointestinal; Reproductive & Urologic; Dermatologic & Dental
DB4 Anti-Infective & Ophthalmology; Anti-Viral; Special Pathogen & Transplant
DB5 Oncology Biologics; Oncology Drugs; Imaging & Hematology
DB6 Generics; Pharmacology & Toxicology; Chemistry & Manufacturing; Special Projects
DB7 Quantitative Safety & Pharmacoepidemiology
![Page 7: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/7.jpg)
7
Typical Activities for an OB Statistician
• Review the statistical aspects of the drug development process
• Present at the advisory committee meeting
• Provide the statistical perspective to policy and guidance working groups
• Continue to develop professionally:– Conduct research on regulatory science
– Participate/ Present at Professional Meetings
![Page 8: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/8.jpg)
8
CDER Drug/Biologic Review Team
• Clinicians • Statisticians• Clinical Pharmacologists• Chemists• Pharmacologists /Toxicologists• Microbiologists• Safety Reviewer • Project Managers• Other Scientists, if needed
![Page 9: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/9.jpg)
9
Communication Dynamics between FDA and Industry
Project Manager
ClinicalStats
Micro
ClinPharm
Chem
Pharm/Tox
Regulatory Affairs
Project Team
![Page 10: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/10.jpg)
10
Types of Applications
• IND: Investigational New Drug Application• NDA: New Drug Application• BLA: Biologics License Application
![Page 11: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/11.jpg)
11
Statistical Review of NDA/BLA
• Review study protocol and conduct of trial and sponsor’s analyses
• Perform additional analyses, if necessary– Re-analyze the primary efficacy data– Conduct sensitivity analyses
• Review proposed label
![Page 12: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/12.jpg)
12
Advisory Committee Meetingshttp://www.fda.gov/AdvisoryCommittees/default.htm
http://www.fda.gov/ohrms/dockets/ac/acmenu.htm
• Typical issues at these meetings– Safety, efficacy, risk/benefits questions– Dosing concerns– Target population or labeling issues– Guidelines/Study/Protocol designs– Appeals of FDA decision
![Page 13: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/13.jpg)
13
CDER Special Government Employees(Partial List)
Victor De Gruttola Thomas FlemmingDavid Harrington Richard GelberJames H. Ware Daniel OakesLee-Jen Wei Stephen GeorgeMarvin Zelen Daniel GillenDianne Finkelstein Michael GinsworldDavid Schoenfield Robert HamerScott Evans Joan HsuPhillip Lavin Andrew LeonJanet Anderson James NeatonJohn C. Crawley David MeMetsLi Ming Dong Weichung ShihDianne Sisfo Thomas Ten HaveRobert Woolson Mary LindstromYing Lu Warren B. BilkerDaniel Sargent
![Page 14: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/14.jpg)
14
Guidance for Industry Adaptive Design Clinical Trials
DRAFT GUIDANCEThis guidance document is being distributed for comment purposes only.
Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.
For questions regarding this draft document contact Robert O’Neill or Sue-Jane Wang at 301-796-1700, Marc Walton at 301-796-2600 (CDER), or the Office of Communication, Outreach and Development (CBER) at 301-800-835-4709 or 301-827-1800. U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
January 2010
Clinical/Medical
![Page 15: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/15.jpg)
15
Guidance for Industry Non-Inferiority Clinical Trials
DRAFT GUIDANCEThis guidance document is being distributed for comment purposes only.
Comments and suggestions regarding this draft document should be submitted within ___ days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.
For questions regarding this draft document contact Robert O’Neill or Robert Temple (CDER) at 301-796-1700, or the Office of Communication
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
January 2010
Clinical/Medical
![Page 16: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/16.jpg)
16
Guidance for Industry Multiple Endpoints in Clinical Trials
DRAFT GUIDANCEThis guidance document is being distributed for comment purposes only.
Comments and suggestions regarding this draft document should be submitted within ___ days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register.
For questions regarding this draft document contact Mohammad Huque, Robert O’Neill or Robert Temple (CDER) at 301-796-1700, or the Office of Communication
U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
January 2010
Clinical/Medical
![Page 17: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/17.jpg)
17
Work in Progress on Other TWO Guidance Documents
• Prevention and Treatment of Missing Data in Clinical Trials- National Academy of Sciences Report
• Meta-Analysis for Safety Evaluation
![Page 18: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/18.jpg)
18
Professional Meetings/ Research Activities
• 4th Annual FDA/DIA Statistics Forum • Midwest Biopharmaceutical Statistics Workshop • DIA Annual Meeting • ICSA 2010 • Applied Statistics Symposium • Joint Statistical Meetings 2010 • FDA/Industry Statistics Workshop
![Page 19: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/19.jpg)
19
The Critical Path to New Medical ProductsThe Critical Path to New Medical Products1. Better Evaluation Tools2. Streamlining Clinical Trials
– Adaptive Trial Designs– Non-inferiority Trials– Multiple Endpoints in Clinical Trials– Enriched Trial Designs
3. Harnessing Bioinformatics4. Moving Manufacturing into the 21st Century5. Developing Approaches to Address Urgent Public Health
Needs• Sentinel Initiative*
6. Specific At-Risk Populations -- Pediatrics
http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiativehttp://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative
![Page 20: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/20.jpg)
20
Regulatory Science and Review Enhancement (RSR)
• CDER Regulatory Science and Review • Enhancement Program
– RSR MaPP– Overview of 2011 RSR Program
• RSR 2011 Cycle *Updated* (Deadline July 16, 2010)– Call for 2011 RSR Applications
– Guidelines for RSR 2011
– RSR 2011 Application Form
– Instructions for Completion, Approval and Submission of RSR Application Form
• RSR Presentations and Awardees (2007-2009)
![Page 21: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/21.jpg)
21
CDER Science Projects and Publications Databases
• The CDER Science Projects Database contains basic information about all CDER science and research projects and programs in a searchable format. The database was developed as an information and research management tool. It provides an opportunity for each investigator to clearly communicate the rationale, impact and relevance of their project/program to a broad audience.
• All CDER science projects and programs must have an entry in the Research Database. If your project is not in the database, please contact your Division Director. They can contact Jorge Urrutia.
• The CDER Publications Database captures publications and abstracts from the entire FDA. CDER publications resulting from research projects in CDER link back to the corresponding project description in the CDER Science Project Database.
• Please check that your publications are in the database by performing a Custom Search using your last name in the Author field. If some of your publications are missing, please click on Add Entry link on the Publications Database page to enter them, or email the citations to Tom Maudru.
![Page 22: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/22.jpg)
22
FDA Commissioner’s Fellowship Program
• Two-year Program, which provides an opportunity for health professionals and scientists to receive training and experience at the FDA.
• Designed to provide in-depth understanding of science behind regulatory review, drugs, devices, biologics and cosmetics
• OB Preceptor: Dr. Ram C. Tiwari, Associate Director• http://inside.fda.gov:9003/EmployeeResources/
EmploymentOpportunities/CommissionersFellowshipProgram/default.htm
![Page 23: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/23.jpg)
23
Internship Program
• Oak Ridge Institute for Science and Education (ORISE) Internship program
– The Office of Biostatistics has contracted with ORISE to administer a summer internship program to enable graduate students in statistics to work with some of our staff on important research projects.
• http://see.orau.org/
• Internships through CP and RSR Projects
![Page 24: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/24.jpg)
24
For More Information about Careers in Statistics at FDA:
•For Links to employment information: http://www.fda.gov/cder/Offices/Biostatistics/
http://www.fda.gov/jobs/positions08.html
•For U.S. Citizens: http://www.usajobs.opm.gov
•For U.S. Citizens and non-U.S. Citizens, both with and without green cards: Contact/send resumes to S. Edward Nevius, Deputy Director, FDA/CDER Office of Biostatistics: [email protected]
![Page 25: 1 Office of Biostatistics Center of Drug Evaluation and Research, FDA Presented at ASA Caucus of Academic Representatives Ram Tiwari, Ph.D. Office of Biostatistics](https://reader036.vdocuments.site/reader036/viewer/2022062303/5514bd66550346b0478b45d6/html5/thumbnails/25.jpg)
25
Concluding Remarks
The Office of Biostatistics, CDER, would welcome academic institutions’ increased participation in:
• FDA Advisory Committees
• OB Ambassadors Program
• Commissioner’s Fellowship
•Internship Program
• Sabbatical/Visitors